Amneal Pharmaceuticals (AMRX) AI Stock Analysis

• Market Cap: $2.51B
• Dividend Yield: N/A
• Average Volume (3M): 1.56M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.73
• Revenue Growth: 13.42%
• EPS Growth: 92.50%
• Country: US
• Employees: 8,300
• Sector: Healthcare
• Sector Strength: 37
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.21
• Shares Outstanding: 313,419,600
• 10 Day Avg. Volume: 1,245,997
• 30 Day Avg. Volume: 1,564,434
• PEG Ratio: -2.21
• Price to Book (P/B): 2.53
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 16.49
• Enterprise Value/Market Cap: 2.54
• Enterprise Value/Revenue: 0.58
• Enterprise Value/Gross Profit: 6.14
• Enterprise Value/Ebitda: 2.82
• 1Y Price Target: $10.33
• Price Target Upside: 29.13% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

• Rating: 56 Neutral
• Price Target: $8.00 ▲(0.00%Upside)

Amneal Pharmaceuticals displays a robust growth trajectory in key segments and strategic initiatives. However, the company's financial challenges, particularly profitability and high leverage, weigh heavily on the overall stock score. Technical indicators and valuation metrics provide mixed signals, but recent earnings calls and corporate events offer a more positive outlook.

Positive Factors

Business Positioning

AMRX's generics business is increasingly well-positioned with a portfolio more focused on complex products and biosimilars, supporting sustainable growth over the next several years.

Product Launch

With the Crexont launch off to a solid start and continued momentum elsewhere across the portfolio, analyst upgrades AMRX to OW from N.

Negative Factors

Market Caution

There is a more mixed view on Crexont and more caution than the Street on overall Gx fundamentals longer-term.

Amneal Pharmaceuticals Business Overview & Revenue Model

Company Description

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, promotion, distribution, and sale of branded pharmaceutical products with focus on central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas. It also offers Emverm, a chewable tablet for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; Rytary to treat Parkinson's disease; and Unithroid for the treatment of hypothyroidism. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. It is also involved in the wholesale distribution of bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names, as well as medical and surgical products; and packaging and wholesale distribution of pharmaceuticals and vitamins to its retail and institutional customers. The company sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. It operates in the United States, India, Ireland, and internationally. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

How the Company Makes Money

Amneal Pharmaceuticals makes money through the development, production, and sale of its pharmaceutical products. The company's primary revenue streams include the sale of generic and specialty pharmaceutical products to wholesalers, distributors, and retail pharmacy chains. Amneal's earnings are bolstered by its extensive portfolio of generic drugs, which allows it to offer cost-effective alternatives to brand-name medications. Additionally, the company invests in research and development to expand its product offerings and enter new therapeutic areas, which can lead to increased sales. Key partnerships and collaborations with other pharmaceutical companies and healthcare providers also contribute to Amneal's revenue by enabling the company to access new markets and enhance its product distribution.

Amneal Pharmaceuticals Financial Statement Overview

Summary

Amneal Pharmaceuticals demonstrates solid revenue growth and improving operational margins. However, the company struggles with profitability due to high leverage and persistent net losses, posing financial stability risks.

Income Statement

Amneal Pharmaceuticals shows a steady revenue growth trajectory, with a TTM revenue increase to $2.83 billion. Gross profit margins remain healthy at approximately 36.7% TTM, but the company continues to struggle with profitability, evidenced by a negative net income. EBIT and EBITDA margins have improved to 12.7% and 18.1% TTM, respectively, reflecting better operational efficiency, although net profit margin is negative due to persistent losses.

Balance Sheet

The company faces high leverage with a debt-to-equity ratio of approximately 1.33 TTM, indicating substantial reliance on debt financing. The equity ratio is concerning at 30.2% TTM, reflecting limited equity buffer against liabilities. Amneal's return on equity remains negative due to ongoing net losses, highlighting challenges in generating shareholder returns.

Cash Flow

Amneal's cash flow position is relatively stable, with positive operating cash flow of $306.9 million TTM, and a consistent free cash flow generation of $238.5 million TTM. The operating cash flow to net income ratio is strong, although free cash flow to net income is strained by negative earnings, indicating adequate but pressured cash management.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.79B	2.39B	2.21B	2.09B	1.99B
Gross Profit	1.02B	820.57M	791.46M	783.95M	628.39M
EBITDA	439.77M	399.76M	150.43M	401.10M	345.61M
Net Income	-116.89M	-83.99M	-129.99M	10.62M	91.06M
Balance Sheet
Total Assets	3.50B	3.47B	3.80B	3.94B	4.01B
Cash, Cash Equivalents and Short-Term Investments	110.55M	93.74M	27.80M	248.96M	341.38M
Total Debt	2.59B	2.75B	2.85B	2.88B	2.94B
Total Liabilities	3.61B	3.45B	3.59B	3.57B	3.66B
Stockholders Equity	-109.27M	19.78M	298.42M	360.34M	344.93M
Cash Flow
Free Cash Flow	243.18M	276.39M	-25.50M	189.18M	312.81M
Operating Cash Flow	295.10M	345.58M	65.10M	241.82M	379.00M
Investing Cash Flow	-63.00M	-69.19M	-174.31M	-194.18M	-317.55M
Financing Cash Flow	-211.79M	-212.57M	-106.62M	-138.12M	131.81M

Amneal Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 8.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AMRX, the sentiment is Neutral. The current price of 8 is below the 20-day moving average (MA) of 8.21, above the 50-day MA of 7.83, and below the 200-day MA of 8.10, indicating a neutral trend. The MACD of 0.04 indicates Positive momentum. The RSI at 47.40 is Neutral, neither overbought nor oversold. The STOCH value of 32.12 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AMRX.

Amneal Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ANIP	75 Outperform	$1.45B	―	-5.19%	―	30.26%	-173.36%
SUPN	71 Outperform	$1.85B	29.85	6.32%	―	11.82%	―
AMPH	68 Neutral	$1.06B	8.17	19.90%	―	8.05%	-8.46%
PRGO	63 Neutral	$3.86B	―	-3.64%	4.03%	-4.85%	-4290.31%
AMRX	56 Neutral	$2.51B	―	106.97%	―	13.42%	92.50%
Sector *	52 Neutral	$7.61B	0.10	-63.03%	2.08%	16.34%	0.32%
ALVO	49 Neutral	$2.76B	27.16	128.44%	―	539.47%	―

Amneal Pharmaceuticals Corporate Events

Amneal Pharmaceuticals Prices $600M Senior Notes Offering

On July 24, 2025, Amneal Pharmaceuticals announced that its subsidiary priced a $600 million offering of senior secured notes due 2032, reduced from the initially planned $750 million. The company plans to use the proceeds from these notes and a $2.1 billion term loan to refinance existing loans and repay outstanding amounts, with the offering expected to close on August 1, 2025, subject to customary conditions.

The most recent analyst rating on (AMRX) stock is a Hold with a $9.00 price target. To see the full list of analyst forecasts on Amneal Pharmaceuticals stock, see the AMRX Stock Forecast page.

Amneal Pharmaceuticals Seeks $1.8 Billion in New Loans

On July 21, 2025, Amneal Pharmaceuticals announced that its subsidiary, Amneal Pharmaceuticals LLC, is seeking to borrow $1.8 billion in new seven-year term B loans and has launched a $750 million private offering of senior secured notes due 2032. The proceeds from these financial activities are intended to refinance existing term B loans, repay a portion of outstanding amounts under its ABL facility, and cover related fees and expenses. These transactions are subject to market conditions, and there is no assurance of their completion. The notes will be offered to qualified institutional buyers and non-U.S. persons, and will not be registered under the Securities Act of 1933.

The most recent analyst rating on (AMRX) stock is a Hold with a $9.00 price target. To see the full list of analyst forecasts on Amneal Pharmaceuticals stock, see the AMRX Stock Forecast page.

Amneal Pharmaceuticals Board Restructuring Amidst Financial Growth

Amneal Pharmaceuticals announced a reduction in its Board of Directors from six to five members due to a decrease in the ownership of Class A Common Stock by the Amneal Group. This led to the resignation of Emily Peterson Alva from the Board on July 16, 2025. The company also reported preliminary financial results for the second quarter of 2025, showing a net revenue increase of approximately 3% and a significant rise in income before taxes compared to the same period in 2024. The results highlight Amneal’s continued financial strength and deleveraging efforts, with expectations to meet or exceed full-year guidance. The quarter also saw the FDA approval of Brekiya® autoinjector and strong commercial uptake of CREXONT®, positioning Amneal well for future growth.

The most recent analyst rating on (AMRX) stock is a Hold with a $9.00 price target. To see the full list of analyst forecasts on Amneal Pharmaceuticals stock, see the AMRX Stock Forecast page.

Amneal Pharmaceuticals Approves Key Proposals at Annual Meeting

Amneal Pharmaceuticals held its 2025 Annual Meeting of Stockholders on May 6, 2025, where all proposals were approved, and all director nominees were elected. The meeting included the election of directors, approval of executive compensation, and ratification of Ernst & Young LLP as the independent auditor for the fiscal year ending December 31, 2025. These approvals are expected to support the company’s governance and operational strategies moving forward.

Amneal Pharmaceuticals Reports Strong Q1 2025 Financial Results

Amneal Pharmaceuticals reported strong financial results for the first quarter of 2025, with net revenue reaching $695 million, a 5% increase from the previous year. The company achieved a net income of $12 million, a significant improvement from a net loss of $92 million in the same quarter of 2024, driven by higher revenue, gross profit, and the absence of a previous legal settlement charge. The company also reported an adjusted EBITDA of $170 million, reflecting a 12% increase, and affirmed its full-year 2025 financial guidance, indicating confidence in its growth trajectory and value creation for stakeholders.